Inhibitory effect of matrilysin antisense oligonucleotides on human colon cancer cell invasion in vitro. 1998

N Momiyama, and N Koshikawa, and T Ishikawa, and Y Ichikawa, and S Hasegawa, and Y Nagashima, and M Mitsuhashi, and K Miyazaki, and H Shimada
Second Department of Surgery, Yokohama City University School of Medicine, Yokohama, Japan.

In colorectal cancer, matrilysin (matrix metalloproteinase-7) is mainly produced by the tumor cells themselves and is thought to play an important role in tumor invasion and metastasis. In the study reported here, we examined the effects of matrilysin antisense phosphorothioate oligonucleotides on both the expression of matrilysin and the invasive potential of the human colon cancer cell line CaR-1 in vitro. To select the most specific and potent oligonucleotide sequence, we performed extensive analyses of the binding specificities of all antisense candidates in the GenBank database by using a computer program we developed. As a result, a 15-mer matrilysin-specific antisense oligonucleotide that hybridizes to the coding region of matrilysin mRNA (AS-1) and a random control oligonucleotide (CL-1) were designed. Reverse transcription-polymerase chain reaction and western blot analysis demonstrated that 10 microM AS-1 suppressed matrilysin expression at both the mRNA level (92%) and protein level (64%). In vitro invasion assays demonstrated that this same concentration of AS-1 inhibited the ability of cells to invade a reconstituted basement membrane by 50% as compared with the ability of untreated cells to do so. On the other hand, CL-1, which had the same length and GC content as AS-1, did not show any inhibitory effect. These results demonstrate that the antisense oligonucleotide AS-1 inhibits matrilysin activities in a sequence-specific manner and suggest that AS-1 has the potential to be used as an anti-metastatic agent in an in vivo experimental model of colon cancer.

UI MeSH Term Description Entries
D008666 Metalloendopeptidases ENDOPEPTIDASES which use a metal such as ZINC in the catalytic mechanism. Metallo-Endoproteinases,Metalloendopeptidase
D009361 Neoplasm Invasiveness Ability of neoplasms to infiltrate and actively destroy surrounding tissue. Invasiveness, Neoplasm,Neoplasm Invasion,Invasion, Neoplasm
D003110 Colonic Neoplasms Tumors or cancer of the COLON. Cancer of Colon,Colon Adenocarcinoma,Colon Cancer,Cancer of the Colon,Colon Neoplasms,Colonic Cancer,Neoplasms, Colonic,Adenocarcinoma, Colon,Adenocarcinomas, Colon,Cancer, Colon,Cancer, Colonic,Cancers, Colon,Cancers, Colonic,Colon Adenocarcinomas,Colon Cancers,Colon Neoplasm,Colonic Cancers,Colonic Neoplasm,Neoplasm, Colon,Neoplasm, Colonic,Neoplasms, Colon
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D001692 Biological Transport The movement of materials (including biochemical substances and drugs) through a biological system at the cellular level. The transport can be across cell membranes and epithelial layers. It also can occur within intracellular compartments and extracellular compartments. Transport, Biological,Biologic Transport,Transport, Biologic
D012333 RNA, Messenger RNA sequences that serve as templates for protein synthesis. Bacterial mRNAs are generally primary transcripts in that they do not require post-transcriptional processing. Eukaryotic mRNA is synthesized in the nucleus and must be exported to the cytoplasm for translation. Most eukaryotic mRNAs have a sequence of polyadenylic acid at the 3' end, referred to as the poly(A) tail. The function of this tail is not known for certain, but it may play a role in the export of mature mRNA from the nucleus as well as in helping stabilize some mRNA molecules by retarding their degradation in the cytoplasm. Messenger RNA,Messenger RNA, Polyadenylated,Poly(A) Tail,Poly(A)+ RNA,Poly(A)+ mRNA,RNA, Messenger, Polyadenylated,RNA, Polyadenylated,mRNA,mRNA, Non-Polyadenylated,mRNA, Polyadenylated,Non-Polyadenylated mRNA,Poly(A) RNA,Polyadenylated mRNA,Non Polyadenylated mRNA,Polyadenylated Messenger RNA,Polyadenylated RNA,RNA, Polyadenylated Messenger,mRNA, Non Polyadenylated
D013873 Thionucleotides Nucleotides in which the base moiety is substituted with one or more sulfur atoms.
D014158 Transcription, Genetic The biosynthesis of RNA carried out on a template of DNA. The biosynthesis of DNA from an RNA template is called REVERSE TRANSCRIPTION. Genetic Transcription
D015971 Gene Expression Regulation, Enzymologic Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control of gene action in enzyme synthesis. Enzymologic Gene Expression Regulation,Regulation of Gene Expression, Enzymologic,Regulation, Gene Expression, Enzymologic

Related Publications

N Momiyama, and N Koshikawa, and T Ishikawa, and Y Ichikawa, and S Hasegawa, and Y Nagashima, and M Mitsuhashi, and K Miyazaki, and H Shimada
April 1995, International journal of cancer,
N Momiyama, and N Koshikawa, and T Ishikawa, and Y Ichikawa, and S Hasegawa, and Y Nagashima, and M Mitsuhashi, and K Miyazaki, and H Shimada
November 2004, Ai zheng = Aizheng = Chinese journal of cancer,
N Momiyama, and N Koshikawa, and T Ishikawa, and Y Ichikawa, and S Hasegawa, and Y Nagashima, and M Mitsuhashi, and K Miyazaki, and H Shimada
January 2001, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine,
N Momiyama, and N Koshikawa, and T Ishikawa, and Y Ichikawa, and S Hasegawa, and Y Nagashima, and M Mitsuhashi, and K Miyazaki, and H Shimada
November 2004, Ai zheng = Aizheng = Chinese journal of cancer,
N Momiyama, and N Koshikawa, and T Ishikawa, and Y Ichikawa, and S Hasegawa, and Y Nagashima, and M Mitsuhashi, and K Miyazaki, and H Shimada
August 2000, Japanese journal of cancer research : Gann,
N Momiyama, and N Koshikawa, and T Ishikawa, and Y Ichikawa, and S Hasegawa, and Y Nagashima, and M Mitsuhashi, and K Miyazaki, and H Shimada
November 1992, Nucleic acids research,
N Momiyama, and N Koshikawa, and T Ishikawa, and Y Ichikawa, and S Hasegawa, and Y Nagashima, and M Mitsuhashi, and K Miyazaki, and H Shimada
July 1999, Biochemical pharmacology,
N Momiyama, and N Koshikawa, and T Ishikawa, and Y Ichikawa, and S Hasegawa, and Y Nagashima, and M Mitsuhashi, and K Miyazaki, and H Shimada
September 1997, Neurochemistry international,
N Momiyama, and N Koshikawa, and T Ishikawa, and Y Ichikawa, and S Hasegawa, and Y Nagashima, and M Mitsuhashi, and K Miyazaki, and H Shimada
July 2004, Ai zheng = Aizheng = Chinese journal of cancer,
N Momiyama, and N Koshikawa, and T Ishikawa, and Y Ichikawa, and S Hasegawa, and Y Nagashima, and M Mitsuhashi, and K Miyazaki, and H Shimada
October 2003, British journal of cancer,
Copied contents to your clipboard!